Effects of neuronal nicotinic acetylcholine receptor allosteric modulators in animal behavior studies.

Chukchi Campus, Department of Bio-science, College of Rural and Community Development, University of Alaska Fairbanks, P.O. Box-297, Kotzebue, AK. 99752-0297. USA. Electronic address: .
Biochemical pharmacology (Impact Factor: 4.65). 05/2013; DOI: 10.1016/j.bcp.2013.05.018
Source: PubMed

ABSTRACT Nicotinic acetylcholine receptors (nAChRs) are ligand-gated cation-conducting transmembrane channels from the cys-loop receptor superfamily. The neuronal subtypes of these receptors (e.g. the α7 and α4β2 subtypes) are involved in neurobehavioral processes such as anxiety, the central processing of pain, food intake, nicotine seeking behavior, and a number of cognitive functions like learning and memory. Neuronal nAChR dysfunction is involved in the pathophysiology of many neurological disorders, and behavioral studies in animals are useful models to assess the effects of compounds that act on these receptors. Allosteric modulators are ligands that bind to the receptors at sites other than the orthosteric site where acetylcholine, the endogenous agonist for the nAChRs, binds. While conventional ligands for the neuronal nAChRs have been studied for their behavioral effects in animals, allosteric modulators for these receptors have only recently gained attention, and research on their behavioral effects is growing rapidly. Here we will discuss the behavioral effects of allosteric modulators of the neuronal nAChRs.

Download full-text


Available from: Anshul Pandya, Feb 20, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The neuronal nicotinic alpha7-acetylcholine receptor (α7-nAChR) is a promising and attractive drug target for improving cognitive deficits in neuropsychiatric and neurological disorders such as Alzheimer's disease (AD). α7-nAChR belongs to the family of ligand gated ion channels. α7-nAChR is expressed in key brain regions (e.g. pre- and frontal cortex, hippocampus). It is involved in essential cognitive functions such as memory, thinking, comprehension, learning capacity, calculation, orientation, language, and judgment. α7-nAChR binds to amyloid peptide (Aβ) inducing either receptor activation or inhibition in an Aβ concentration-dependent mode. Aβ oligomers induce  phosphorylation via α7-nAChR activation. α7-nAChR agonists and/or α7-nAChR positive allosteric modulators may be useful in AD therapy. The current review enlightens: (i) α7-nAChR neurobiology, (ii) α7-nAChR role in cognition and (iii) in AD, and (iv) the clinical status of the most promising molecules for the treatment of cognitive dysfunction in AD.
    Current pharmaceutical design 03/2014; · 3.29 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The native α7 nicotinic acetylcholine receptor (α7nAChR) is a homo-pentameric ligand-gated ion channel mediating fast synaptic transmission, and is of pharmaceutical interest for treatment of numerous disorders. The transmembrane domain (TMD) of α7nAChR has been identified as a target for positive allosteric modulators (PAMs), but it is unclear whether modulation occurs through changes entirely within the TMD or changes involving both the TMD and the ECD-TMD interface. In this study, we constructed multiple chimeras using the TMD of human α7nAChR and the extracellular domain (ECD) of a prokaryotic homolog, ELIC, which is not sensitive to these modulators, and for which a high-resolution structure has been solved. Functional ELIC-α7nAChR (EA) chimeras were obtained when their ECD-TMD interfaces were modified to resemble either the ELIC interface (EAELIC) or α7nAChR interface (EAα7). Both EAα7 and EAELIC show similar activation response and desensitization characteristics, but only EAα7 retained the unique pharmacology of α7nAChR evoked by PAMs, including potentiation by ivermectin, PNU-120596, and TQS, as well as activation by 4BP-TQS. This study suggests that PAM modulation through the TMD has a more stringent requirement at the ECD-TMD interface than agonist activation.
    Journal of Biological Chemistry 04/2014; 289(20). DOI:10.1074/jbc.M113.524611 · 4.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Clinical and pre-clinical evidence suggest that α7 nicotinic acetylcholine receptor activation (α7nAChR) improves cognitive function, decline of which is associated with conditions such as Alzheimer's disease and schizophrenia. Moreover, allosteric modulation of α7nAChR is an emerging therapeutic strategy in attempt to avoid the rapid desensitization properties associated with the α7nAChR following orthosteric activation. We used a calcium assay to screen for positive allosteric modulators (PAMs) of α7nAChR and report on pharmacological characterization of the novel compound RO5126946 (5-Chloro-N-[(1S,3R)-2,2-dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-2-methoxy-benzamide) which allosterically modulates α7nAChR activity. RO5126946 increased ACh-evoked peak current and delayed current decay, but did not affect recovery of α7nAChRs from desensitization. In addition, RO5126946 effects were absent when nicotine-evoked currents were completely blocked by co-application of the α7nAChR-selective antagonist methyllycaconitine. RO5126946 enhanced α7nAChR synaptic transmission and positively modulated GABAergic responses. Absence of RO5126946 effects at human α4β2nAChR and 5HT3 receptors, amongst others, indicated selectivity for α7nAChRs. In vivo, RO5126946 is orally bioavailable, brain-penetrant and improves associative learning in a scopolamine-induced deficit model of fear conditioning in rat. In addition, pro-cognitive effects of RO5126946 were investigated in presence of nicotine to address potential pharmacological interactions on behavior. RO5126946 potentiated nicotine's effects on fear memory when both compounds were administered at sub-threshold doses and did not interfere with pro-cognitive effects observed when both compounds were administered at effective doses. Overall, RO5126946 is a novel α7nAChR PAM with cognitive enhancing properties.
    Journal of Pharmacology and Experimental Therapeutics 06/2014; 350(2). DOI:10.1124/jpet.113.210963 · 3.86 Impact Factor